AnxVaxTecM TM
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Bivalent vaccine for Anthrax with outer surface of the nanoparticle is synthesized to mimic the surface of Bacillus anthracis and outer surface has stabilized antigen PA. Dual antigen vaccine showed 4 fold increase in antibody production than in single antigen vaccine for PA. Animal data available.
Adjunct Synergetic PD-L1 Therapy
A qualified nanoparticle system capable of helping synergistically PD-L1 therapy has been in development with RxBiosciences, Gaithersburg MD. Combining PD-L1 inhibitor with a CTLV-4 inhibitor and TIGIT simultaneously holds great promise in immunotherapy. Product is in preclinical phase as yet.
